Select Medical supplements merger proxy with deal fees, DCF details after stockholder suits

SELECT MEDICAL HOLDINGS CORP

Three lawsuits in NY and PA allege proxy omissions; company denies but voluntarily adds disclosures.
Adds $2.9M fee to Ortenzio and $0.2M to Jackson for roles in structuring the transaction.
Board explored separating critical illness recovery hospital segment from late June 2025.
Goldman Sachs DCF valuation range per share: $15.04-$25.33; net debt $1.818B; 17 precedent deal premia added.
Special meeting on merger remains scheduled for June 26, 2026; company urges stockholders to vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.